The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder?
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Abstract Introduction: Obsessive-compulsive disorder (OCD) is a disabling illness that is associated with significant functional impairment. Although evidence-based pharmacotherapies exist, currently available medications are ineffective in some patients and may cause intolerable side effects in others. There is an urgent need for new treatments. Discussion: A growing body of basic and clinical research has showed that the endocannabinoid system (ECS) plays a role in anxiety, fear, and repetitive behaviors. At the same time, some patients with OCD who smoke cannabis anecdotally report that it relieves their symptoms and mitigates anxiety, and several case reports describe patients whose OCD symptoms improved after they were treated with cannabinoids. Taken together, these findings suggest that the ECS could be a potential target for novel medications for OCD. In this study, we review evidence from both animal and human studies that suggests that the ECS may play a role in OCD and related disorders. We also describe findings from studies in which cannabinoid drugs were shown to impact symptoms of these conditions. Conclusions: An emerging body of evidence suggests that the ECS plays a role in OCD symptoms and may be a target for the development of novel medications. Further exploration of this topic through well-designed human trials is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 2×
“Exogenous cannabinoids, including THC and CBD, have been shown to reduce rodent responsiveness to conditioned fear,(42,43) while selective CB1R antagonists appear to inhibit the extinction process.(39) Animal studies also show that the metabolic enzymes”
BackgroundAn Introduction to the Endogenous Cannabinoid System
Lu, H.-C., & Mackie, K. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.07.028 · Cited by 1,234
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059 · cited 8×
“This effect was driven by paracetamol’s effect at both 5HT receptors and CB1R.”
BackgroundInfluentialObsessive-compulsive disorder: beyond segregated cortico-striatal pathways
Milad, M. R., & Rauch, S. L. (2012) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.11.003 · Cited by 847 · cited 11×
“In contrast, THC and exogenous cannabinoids decrease the stress response at low doses while increasing it at high doses.38 Taken together, these findings suggest that CB1R acts as a buffer on activity within anxiety circuits, exerting opposing effects depending on the dose of agonist and aversiveness of the local envi…”
BackgroundInfluentialNeuroimaging and frontal–subcortical circuitry in obsessive–compulsive disorder
Saxena, S., Brody, A. L., Schwartz, J. M., & Baxter, L. R. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000297870 · Cited by 831
Disorders of compulsivity: A common bias towards learning habits
Voon, V, Derbyshire, K., Rück, C., Irvine, M. A., Worbe, Y., Enander, J., Schreiber, L. R. N., Gillan, C., Fineberg, N. A., Sahakian, B. J., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.44 · Cited by 643 · cited 8×
“In contrast, THC and exogenous cannabinoids decrease the stress response at low doses while increasing it at high doses.38 Taken together, these findings suggest that CB1R acts as a buffer on activity within anxiety circuits, exerting opposing effects depending on the dose of agonist and aversiveness of the local envi…”
BackgroundInfluentialBloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635
Multiple Functions of Endocannabinoid Signaling in the Brain
Katona, I., & Freund, T. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062111-150420 · Cited by 630 · cited 1×
“CB1R activation also impacts anxiety by modulating activity in excitatory and inhibitory outputs from the cortex.(34) In mouse studies, CB1R agonists at low doses (which are anxiolytic) primarily activate CB1R in corti-”
BackgroundThe endocannabinoid system in guarding against fear, anxiety and stress
Lutz, B., Marsicano, G., Maldonado, R., & Hillard, C. J. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn4036 · Cited by 506
Early phytocannabinoid chemistry to endocannabinoids and beyond
Mechoulam, R., Hanuš, L. O., Pertwee, R., & Howlett, A. C. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3811 · Cited by 393 · cited 1×
“Although efforts to study the properties of tetrahydrocannabinol (THC, the primary psychoactive ingredient in the cannabis plant) began in the early 1940s, its endogenous receptor, the cannabinoid receptor type 1 (CB1R), was not identified until 1988.(20) Since then, Table 1.”
Background
Cited by
Capuzzi, E., Di Brita, C., Caldiroli, A., Colmegna, F., Nava, R., Buoli, M., & Clerici, M. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113463 · Cited by 132
Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder
Grassi, G., Cecchelli, C., Vignozzi, L., & Pacini, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s255375 · Cited by 44
Rasera, G. B., Ohara, A., & de Castro, R. J. S. (2021) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2021.06.035 · Cited by 44
Innovations in the delivery of exposure and response prevention for obsessive-compulsive disorder
Patel, S. R., Comer, J., & Simpson, H. B. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2020_202 · Cited by 24
Self-citation
Metadata
- Authors
- Kayser, R. R., Snorrason, I., Haney, M., Lee, F. S., & Simpson, H. B.
- Venue
- Cannabis and Cannabinoid Research
- Publisher
- SAGE Publications
- Published
- 2019-06
- Volume
- 4
- Issue
- 2
- Pages
- 77-87
- ISSN
- 2378-8763 (ISSN-L)
- OpenAlex
- W2947131253
- Cited by
- 35
- References
- 23
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder? https://app.cochat.ai/papers/10.1089/can.2018.0049
- The paper
- Kayser, R. R., Snorrason, I., Haney, M., Lee, F. S., & Simpson, H. B. (2019). The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder? Cannabis and Cannabinoid Research. https://doi.org/10.1089/can.2018.0049
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.